Tigermed to snag top-end price for $1.4bn Hong Kong IPO

biopharma_stocks_adobe_575x375.jpg
By Jonathan Breen
31 Jul 2020

Hangzhou Tigermed Consulting is set to pocket HK$10.7bn ($1.38bn) from its Hong Kong secondary listing, with solid support from Chinese and global investors driving final pricing to the top of guidance.

Tigermed is a biopharmaceutical research and development service provider, known as a contract research organisation (CRO). It is already listed on the Shenzhen Stock Exchange, so investors were well acquainted with the company when it hit Hong Kong on Monday.

The IPO was hot off the block ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial